Here's Why Trump's Solution to the Opioid Epidemic is Foolish, Cruel and Bound to Fail

by Nomad

"This Horrible, Horrible Situation"

President Trump has never shied away from talking about the opioid epidemic. In October, he declared it to be a national public health emergency under federal law. He said:

No part of our society — not young or old, rich or poor, urban or rural — has been spared this plague of drug addiction and this horrible, horrible situation that’s taken place with opioids.

Good News Round -Up for Week Two of February 2018

by Nomad

In an endless search of positive news, I scoured the Internet, hunting high and low. and I managed to find these four stories for all my glum Nomads. 

Super Beans for Human Beings

Let's talk beans. Specifically, super beans. 

Developed by scientists at the National Agricultural Research Organisation of Uganda, in collaboration with the Colombia-based International Centre for Tropical Agriculture (CIAT), the Nabe 15 bean is better than your average bean. It's a fast-maturing, high-yield variety that drought-resistant. 

Living and Dying in the Arms of Mother Russia

by Nomad

Here's a peek into some of the reasons why Russians, men, in particular, have a hard time surviving until what we consider middle-age. Sadly for the Russian government, there's not a single reason but a multitude of them. 

Russia is no country for old men. And it's not all that great for old women either. That's not an opinion but a fact.
According to a recent report by the Organization for Economic Cooperation and Development (OECD), most Russian citizens will not see their 71st birthday. But how does that stack up against other countries, you ask?

The life expectancy in the former Communist country lags nearly ten years behind the average in developed countries. That's also lower than countries with similar income levels such as Turkey, Mexico or Chile.

Russia ranked 43rd out of the 45 countries surveyed. The average life expectancy in Russia in 2013 was 70.7 years. but the life expectancy for Russian men is just 64 years. (For U.S. men, the average life expectancy is 76.)

Experts have made some conjectures on why Russians have such a hard time staying alive past their seventh decade.

Up in Smoke

Lifestyle choices are blamed for the poor showing, namely high rates of alcohol abuse, and smoking.
Back in 2013, Putin signed legislation that placed an increased tax on cigarettes raising the price to approximately $1.50 a pack.
(A smoker's paradise compared to most Western countries.)

How Three Asian Nations are Beating Outrageous Price-Gouging by American Pharmas

by Nomad

Some have started to question the exorbitant prices pharmaceutical companies charge the public. In Asia, we may be seeing a push back against what some see as price-gouging of the most desperate and vulnerable segment of the world's population: The sick and the poor.

In the recent past, Nomadic Politics examined, in two posts, alleged price-gouging for one company's drug for Hepatitis C. There are further developments to that story. First, let's re-cap.

The Breakthrough

The story begins with some very good news. It was reported last year that one orally-administered drug,  Sovaldi (sofosbuvir), has proved to be a breakthrough for the treatment of a silent killer virus, hepatitis C.  

From the clinical trial reports, researchers claimed that Sovaldi was not a life-long treatment but a genuine cure for the deadly disease itself. The therapy required a 12-week therapy but at the end, most of the patients would be free of the disease.  

Then came the bad news: Gilead Sciences, the patent-owner and developer of the drug, was definitely not a charity organization. It was a profit-making company which, according to Wikipedia, earned US $12.059 billion in 2014. 

It was immediately clear to everybody that the Hep C cure was not going to be given away free. Few, however, were expecting the price the company settled on. Sovaldi costs $1,000 a day, adding up to staggering $84,000 for a 12-week supply. 

The problem is obvious: at that price, a cure is out of reach of most patients in the world and even in rich countries.

Why Iran's Internal Politics May Soon Make Nuclear Negotiations Impossible

by Nomad

The hopes for some kind of equitable resolution of the Iranian nuclear issue are further complicated by the declining health of the Iranian Supreme Leader, Khamenei. We examine how his death could make any kind of breakthrough next to impossible.

Death as a Catalyst for Change

There's no question about it. Time is running out.
If reports are true, the health of the Iranian Supreme Leader Ali Khamenei is in decline. Western intelligence, as reported by the French paper Le Figaro, says that the 76-year-old has been diagnosed with stage four prostate cancer which has spread to other parts of his body. At most, he has two more years. 

 As Al Jezeera reported last September:

The image of the aging Khamenei recuperating in a hospital bed and being kissed by President Hassan Rouhani has led to speculation about janesheen, or succession, by Iran observers and probably by people at the higher echelons of Iranian politics.

This news is not such a well-kept secret. Concerns about the Supreme Leader's health- as well as, who his successor might be- have been the source of much speculation for the last few years. For all parties concerned, the timing could not possibly be any worse. 

Bust: How Republicans Lost the War on Drugs 3/5

by Nomad

In past installments in this series on America's war on drugs, we examined Nixon and Ford. Now we turn to the Democratic president Jimmy Carter.
Deeply entrenched distrust for the president within the CIA would prove to be an insurmountable obstacle.

Part 3. Where the Rational Met Reality

Carter's Way

The 70s were a time of reformation after the hectic and often frightening social shakeups of the 60s. Watergate and the subsequent Church Senate Committee Investigations had opened up the heart of the political system and most Americans were appalled at the grimy business of running the country and managing the world.

What was needed was a complete overhaul starting at the top. Jimmy Carter, a born-again Christian, peanut farmer with the down-home Georgian accent seemed to be the style of leadership the country demanded.
And so in 1976, against all expectations, The Waltons moved into the White House.

The white middle class conservative values of "dominant social order" were being re-evaluated, questioned and challenged in a variety of ways.

The extreme conservative opinion, typified by white frustration, tainted with bigotry and, simplistic, backward views of the world,  was being mocked weekly on television shows like All in the Family and other programs. It is no surprise then that the failed drug policy should once again come under greater scrutiny.

In some ways, President Carter did, in fact, pick up where President Ford had left off. And as we mentioned in the previous post, that new direction had already been sabotaged. While marijuana was now being considered harmless and non-addictive, cocaine was added to the same category. (We should take a closer look at the possible reason for this.) In any case, this coupling, for whatever reasons, proved to be a major blunder.

Both, under President Ford's directive, were now to receive far less attention from law enforcement. Meanwhile the focus was concentrated on the heroin trade. 

Progress combating the illegal import of heroin too was hampered. That had much to do with the CIA and its antagonism toward Carter and all he represented. 

It was common knowledge that high level intelligence officials in the agency had no great love for Carter. Perhaps it was to be expected since President Carter had campaigned as an outsider who was coming to Washington to clean the mess that the Church Committee had revealed.

Cure for Hepatitis C: The Politics and Profits behind a Breakthrough

by Nomad

A breakthrough in curing a silent killer, Hepatitis C, should mean that patients will have a new lease on life. But unless they are extraordinarily wealthy or they  live in a state that expanded Medicaid in the wake of the Affordable Care Act, these people will be at the mercy of the profit-driven free market. So for most of the uninsured or under-insured Americans, it will mean no cure at all.

Good News 

Even for researchers who are loathe to use the word "cure," there's no question that the news is very good,

The Denver Post is reporting of a breakthrough drug for hepatitis C in clinical trials at the University of Colorado Hospital. This new anti-viral is being called the blockbuster cure for patients who have long had to endure debilitating treatment for this liver-destroying disease.

Astoundingly, Sovaldi, a daily-dose pill manufactured by California-based Gilead Sciences Inc., has cured about 90 percent of patients in only 12 weeks when used with older drugs, studies nationwide have found.

In other words, it's a very nearly the cure for a killer. Not life-long treatment like the HIV drug therapy, but an actual eradication of the affliction. 

A big big deal.

Silent Killer of the Baby Boomers
This is a disease that infects an estimated 150–200 million people around the world. In the US the majority of the estimated 3.2 million people with chronic hepatitis C virus (HCV) are baby boomer adults. Seventy-three percent of hepatitis C deaths were reported among those 45 to 64 years old.
For every 100 people who contract the virus, 75 will develop chronic infection. About 5 to 20 will develop cirrhosis over the next 20 to 30 years. Between 1 and 5 will die of cirrhosis and liver cancer. Meaning, more than 350 000 people die every year from hepatitis C-related liver diseases. The disease is found worldwide with some countries having chronic infection rates as high as 5% and above.

One of the particularly dangerous aspects of the disease is its insidious nature. Most of those infected with the virus do not know that they have it, which means they could easily be spreading it to others via exposure to blood—or, occasionally, sexual contact. The main mode of transmission in countries with infection rates above 5% is attributed to unsafe injections using contaminated equipment.

"In almost every country it is a significant public health problem, points out Charles Gore, president of the World Hepatitis Alliance, "and, in some, such as Egypt, which has 10% to 15% of its population living with hepatitis C, and Vietnam, where the prevalence of hepatitis B is 15% to 20%, it is simply overwhelming."

So curing this disease is unquestionably a great triumph for science. It's something that the researchers should be proud of. 

There is however one problem.

Now...The Bad News

Sovaldi was approved by the Food and Drug Administration (FDA) last December, but it won't be cheap. Sovaldi costs $1,000 a day and that adds up to staggering $84,000 for a 12-week supply.